A Phase IV trial of a hospital policy of Tranexamic acid to reduce transfusion in major non-cardiac surgery (TRACTION)
A pragmatic randomized controlled trial
A pragmatic randomized controlled trial
A Phase IV trial of a hospital policy of Tranexamic acid use to reduce transfusion in major non-cardiac surgery (TRACTION)
Tranexamic acid to reduce transfusion in major non-cardiac surgery
Pragmatic, randomized cluster-crossover trial.
Approximately 8320 patients 18 years of age and with Increased local fibrinolysis undergoing surgeries known to have a baseline transfusion rate of 5% or greater.
Tranexamic acid (TXA)
TXA 1 gram intravenous bolus followed by 1 additional gram prior to skin closure.
From first surgical incision until skin closure.
90 days
18 months
Co-primary outcomes include: a) the proportion of patients transfused red blood cells (RBCs); and b) the incidence of deep vein thrombosis or pulmonary embolus within 3 months of surgery.
(1) Transfusion: The number of RBC units transfused, both at an individual-level and at a cluster-level; (2) Safety: In-hospital diagnosis of myocardial infarction, stroke, deep vein thrombosis or pulmonary embolus; (3) Clinical: Hospital length of stay, ICU admission, hospital survival, 3-month survival, and the number of days at home to day 30 (DAH30); 4) Compliance: proportion of eligible patients who receive the policy intervention, and the policy compliance in enrolled patients.